Incontinentia pigmenti: A window to the role of NF-κB function

Seminars in Cutaneous Medicine and Surgery

Volumn 23, Issue 2, 2004, Pages 116-124

  Bruckner, Anna L ^a  

^a UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIBIOTIC AGENT; EMOLLIENT AGENT; ETRETINATE; IMMUNOGLOBULIN; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; TUMOR NECROSIS FACTOR ALPHA;

ALOPECIA; BACTERIAL INFECTION; BLINDNESS; CENTRAL NERVOUS SYSTEM; CLINICAL FEATURE; CRYOTHERAPY; ECTODERMAL DYSPLASIA; EYE MALFORMATION; GENE MUTATION; HUMAN; INCONTINENTIA PIGMENTI; LASER COAGULATION; NONHUMAN; PROTEIN FUNCTION; RASH; RETINA DETACHMENT; RETINOPATHY; REVIEW; SEIZURE; SKIN ULCER; TOOTH MALFORMATION; TUMOR;

DIAGNOSIS, DIFFERENTIAL; HUMANS; INCONTINENTIA PIGMENTI; NF-KAPPA B;

EID: 3042780504     PISSN: 10855629     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.sder.2004.01.005     Document Type: Review

References (56)

1. Berlin A.L., Paller A.S., Chan L.S. Incontinentia pigmenti A review and update on the molecular basis of pathophysiology. J Am Acad Dermatol. 47:2002;169-187
2. Carney R.G. Incontinentia pigmenti A world statistical analysis. Arch Dermatol. 112:1975;535-542
3. Kenwrick S., Woffendin H., Jakins T., et al. Survival of male patients with incontinentia pigmenti carrying a lethal mutation can be explained by somatic mosaicism or Klinefelter syndrome. Am J Hum Genet. 69:2001;1210-1217
4. Hadj-Rabia S., Froidevaux D., Bodak N., et al. Clinical study of 40 cases of incontinentia pigmenti. Arch Dermatol. 139:2003;1163-1170
5. Bodak N., Hadj-Rabia S., Hamel-Teillac D., et al. Late recurrence of inflammatory first-stage lesions in incontinentia pigmenti An unusual phenomenon and a fascinating pathologic mechanism. Arch Dermatol. 139:2003;201-204
6. Landy S.J., Donnai D. Incontinentia pigmenti (Bloch-Sulzberger syndrome). J Med Genet. 30:1993;53-59
7. Bessems P.J., Jagtman B.A., van de Staak W.J., et al. Progressive, persistent, hyperkeratotic lesions in incontinentia pigmenti. Arch Dermatol. 124:1988;29-30
8. Dutheil P., Vabres P., Hors Cayla M.C., et al. Incontinentia pigmenti: Late sequelae and genotypic diagnosis: A three-generaion study of four patients. Pediatr Dermatol. 12:1995;107-111
9. Wiklund D.A., Weston W.L. Incontinentia pigmenti A four-generation study. Arch Dermatol. 116:1980;701-703
10. Moss C., Ince P. Anhidrotic and achromians lesions in incontinentia pigmenti. Br J Dermatol. 116:1987;839-849
11. Mascaro J.M., Palou J., Vives P. Painful subungal keratotic tumors in incontinentia pigmenti. J Am Acad Dermatol. 13:1985;913-918
12. Simmons D.A., Kegel M.F., Scher R., et al. Sugungal tumors in incontinentia pigmenti. Arch Dermatol. 122:1986;1431-1434
13. Malvehy J., Palou J., Mascaro J.M. Painful subungual tumour in incontinentia pigmenti Response to treatment with etretinate. Br J Dermatol. 138:1998;554-555
14. Goldberg M.F., Custis P.H. Retinal and other manifestations of incontinentia pigmenti (Bloch-Sulzberger syndrome). Ophthalmology. 100:1993;1645-1654
15. Holmstrom G., Thoren K. Ocular manifestations of incontinentia pigmenti. Acta Ophthalmol Scand. 78:2000;348-353
16. Catalano R.A. Incontinentia pigmenti. Am J Ophthalmol. 110:1990;696-700
17. Francis J.S., Sybert V.P. Incontinentia pigmenti. Sem Cut Med Surg. 16:1997;54-60
18. Hubert J.N., Callen J.P. Incontinentia pigmenti presenting as seizures. Pediatr Dermatol. 19:2002;550-552
19. Shuper A., Bryan R.N., Singer H.S. Destructive encephalopathyin incontinentia pigmenti a primary disorder? Pediatr Neurol. 6:1990;137-140
20. Lee A.G., Goldberg M.F., Gillard J.H., et al. Intracranial assessment of incontinentia pigmenti using magnetic resonance imaging, angiography, and spectroscopic imaging. Arch Pediatr Adolesc Med. 149:1995;573-580
21. Fiorillo L., Sinclair D.B., O'Byrne M.L., et al. Bilateral cerebrovascular accidents in incontinentia pigmenti. Pediatr Neurol. 29:2003;66-68
22. Hennel S.J., Ekert P.G., Volpe J.J., et al. Insights into the pathogenesis of cerebral lesions in incontinentia pigmenti. Pediatr Neurol. 29:2003;148-150
23. Dahl M.V., Matula G., Leonards R., et al. Incontinentia pigmenti and defective neutrophil chemotaxis. Arch Dermatol. 111:1975;1603-1605
24. Menni S., Piccinno R., Biolchini A., et al. Immunologic investigations in eight patients with incontinentia pigmenti. Pediatr Dermatol. 7:1990;275-277
25. Machado-Pinto J., McCalmont T.H., Golitz L.E. Eosinophilic and neutrophilic spongiosis Clues to the diagnosis of immunobullous diseases and other inflammatory disorders. Semin Cutan Med Surg. 15:1996;308-316
26. Nazzaro V., Brusasco A., Gelmetti C., et al. Hypochromic reticulated streaks in incontinentia pigmenti An immunohistochemical and ultrastructural study. Pediatr Dermatolol. 7:1990;174-178
27. Zillikens D., Mehringer A., Lechner W., et al. Hypo- and hyperpigmented areas in incontentia pigmenti Light and electron microscopic studies. Am J Dermatopathol. 13:1991;57-62
28. Rogers M., McCrossin I., Commens C. Epidermal nevi and the epidermal nevus syndrome. J Am Acad Dermatol. 20:1989;476-488
29. Kalter D.C., Griffiths W.A., Atherton D.J. Linear and whorled nevoid hypermelanosis. J Am Acad Dermatol. 19:1988;1037-1044
30. Kuster W., Ehrig T., Happle R. Hypomelanosis of Ito and mosaicism. Nordlund J.J., Boissy R.E., Hearing V.J.,, et al. The Pigmentary System Physiology and Pathophysiology. 1998;594-601 Oxford University Press, New York
31. Nehal K.S., PeBenito R., Orlow S.J. Analysis of 54 cases of hypopigmentation and hyperpigmentation along the lines of blaschko. Arch Dermatol. 132:1996;1167-1170
32. Sybert V.P. Incontinentia pigmenti nomenclature. Am J Hum Genet. 55:1994;209-211
33. Happle R. Incontinentia pigmenti versus hypomelanosis of Ito The whys and wherefores of a confusing issue. Am J Med Genet. 79:1998;64-65
34. Catalano R.A., Lopatynsky M., Tasman W.S. Treatment of proliferative retinopathy associated with incontinentia pigmenti. Am J Ophthalmol. 110:1990;701-702
35. Sefiani A., Abel L., Heuertz S., et al. The gene for incontinentia pigmenti is assigned to Xq28. Genomics. 4:1989;427-429
36. Smahi A., Hyden-Granskog C., Peterlin B., et al. The gene for the familial form of incontinentia pigmenti (IP2) maps to the distal part of Xq28. Hum Mol Genet. 3:1994;273-278
37. Jin D.Y., Jeang K.T. Isolation of full-length cDNA and chromosomal localization of human MF-kappaB modulator NEMO to Xq28. J Biomed Sci. 6:1999;115-120
38. Smahi A., Courtois G., Vabres P., et al. Genomic rearrangement in NEMO impairs NF-kappaB activation and is a cause of incontinentia pigmenti. Nature. 405:2000;466-472
39. Smahi A., Courtois G., Hadj-Rabia S., et al. The NF-κB signaling pathway in human diseases from incontinentia pigmenti to ectodermal dysplasias and immune-deficiency syndromes. Hum Mol Genet. 11:2002;2371-2375
40. Parrish J.E., Scheuerle A.E., Lewis R.A., et al. Selection against mutant alleles in blood leukocytes is a consistent feature in incontinentia pigmenti type 2. Hum Molec Genet. 5:1996;1777-1783
41. Happle R. Lyonization and the lines of Blaschko. Hum Genet. 70:1985;200-206
42. Rott H.-D. Extracutaneous analogies of Blaschko lines. Am J Med Genet. 85:1999;338-341
43. Beg A.A., Baltimore D. An essential role for NF-kappaB in preventing TNF-alpha-induced cell death. Science. 274:1996;782-784
44. Van Antwerp D.J., Martin S.J., Verma I.M., et al. Inhibition of TNF-induced apoptosis by NF-kappa B. Trends Cell Biol. 8:1998;107-111
45. Rudolph D., Yeh W.C., Wakeham A., et al. Severe liver degeneration and lack of NF-kappaB activation in NEMO/IKKgamma-deficient mice. Genes Dev. 14:2000;854-862
46. Makris C., Godfrey V.L., Krahn-Senftleben G., et al. Female mice heterozygous for IKK gamma/NEMO deficiencies develop a dermatopathy similar to the human X-linked disorder incontinentia pigmenti. Mol Cell. 5:2000;969-979
47. Schmidt-Supprian M., Bloch W., et al. NEMO/IKK gamma-deficient mice model incontinentia pigmenti. Mol Cell. 5:2000;981-992
48. Jean-Baptiste S., O'Toole E.A., Chen M., et al. Expression of eotaxin, an eosinophil-selective chemokine, parallels eosinophil accumulation in the vesiculobullous stage of incontinentia pigmenti. Clin Exp Immunol. 127:2002;470-478
49. Franzoso G., Carlson L., Xing L., et al. Requirement for NF-κB in osteoclast and B-cell development. Genes Dev. 11:1997;3482-3496
50. Iotsova V., Caamano J., Loy J., et al. Osteopetrosis in mice lacking nf-kappa-b1 and nf-kappa-b2. Nature Med. 3:1997;1285-1289
51. Pinheiro M., Freire-Maia N. Ectodermal dysplasias A clinical classification and a causal review. Am J Med Genet. 53:1994;153-162
52. Zonana J., Elder M.E., Schneider L.C., et al. A novel x-linked disorder of immune deficiency and hypohidrotic ectodermal dysplasia is allelic to incontinentia pigmenti and due to mutations in IKK-gamma (NEMO). Am J Hum Genet. 67:2000;1555-1562
53. Aradhya S., Courtois G., Rajkovic A., et al. Atypical forms of incontinentia pigmenti in male individuals result from mutations of a cytosine tract in exon 10 of NEMO (IKK-γ Am J Hum Genet. 68:2001;765-771
54. Jain A., Ma C.A., Liu S., et al. Specific missense mutations in NEMO result in hyper-IgM syndrome with hypohidrotic ectodermal dysplasia. Nature Immunol. 2:2001;223-228
55. Doffinger R., Smahi A., Bessia C., et al. X-linked anhidrotic ectodermal dysplasia with immunodeficiency is caused by impaired NF-κB signaling. Nature Genet. 27:2001;277-285
56. Mansour S., Woffendin H., Mitton S., et al. Incontinentia pigmenti in a surviving male is accompanied by hypohidrotic ectodermal dysplasia and recurrent infection. Am J Med Genet. 99:2001;172-177